2. NF-κB
  3. Keap1-Nrf2
  4. Eriodictyol-7-O-glucoside

Eriodictyol-7-O-glucoside  (Synonyms: Eriodictyol 7-O-β-D-glucoside)

Cat. No.: HY-N3847 Purity: 99.82%
COA
SDS
Handling Instructions Technical Support

Eriodictyol-7-O-glucoside (Eriodictyol 7-O-β-D-glucoside), a flavonoid, is an Nrf2 activator. Eriodictyol-7-O-glucoside exhibits significant scavenging effects on both hydroxyl radicals and superoxide anions, with IC50 values of 0.28 mM and 0.30 mM, respectively. Eriodictyol-7-O-glucoside increases the nuclear localization of Nrf2 and induces the expression of the Nrf2/ARE-dependent genes. Eriodictyol-7-O-glucoside provides protection against oxygen and glucose deprivation (OGD)-induced oxidative insult. Eriodictyol-7-O-glucoside demonstrates neuroprotective efficacy in a rat model of focal cerebral ischemia (MCAO). Eriodictyol-7-O-glucoside can be used for the study of stroke.

For research use only. We do not sell to patients.

Eriodictyol-7-O-glucoside

Eriodictyol-7-O-glucoside Chemical Structure

CAS No. : 38965-51-4

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Eriodictyol-7-O-glucoside Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Eriodictyol-7-O-glucoside (Eriodictyol 7-O-β-D-glucoside), a flavonoid, is an Nrf2 activator. Eriodictyol-7-O-glucoside exhibits significant scavenging effects on both hydroxyl radicals and superoxide anions, with IC50 values of 0.28 mM and 0.30 mM, respectively. Eriodictyol-7-O-glucoside increases the nuclear localization of Nrf2 and induces the expression of the Nrf2/ARE-dependent genes. Eriodictyol-7-O-glucoside provides protection against oxygen and glucose deprivation (OGD)-induced oxidative insult. Eriodictyol-7-O-glucoside demonstrates neuroprotective efficacy in a rat model of focal cerebral ischemia (MCAO). Eriodictyol-7-O-glucoside can be used for the study of stroke[1][2][3].

IC50 & Target

Nrf2[1]
Cellular Effect
Cell Line Type Value Description References
H9c2 EC50
38.23 μM
Compound: 3
Cytoprotective activity against doxorubicin-induced cytotoxicity in rat H9c2 cells assessed as cell viability after 24 hrs by MTT assay
Cytoprotective activity against doxorubicin-induced cytotoxicity in rat H9c2 cells assessed as cell viability after 24 hrs by MTT assay
[PMID: 20932762]
RAW264.7 IC50
41.2 μM
Compound: 10
Antiinflammatory activity against mouse RAW264.7 cells assessed as Inhibition of LPS-induced nitric oxide production after 24 hrs by ELISA
Antiinflammatory activity against mouse RAW264.7 cells assessed as Inhibition of LPS-induced nitric oxide production after 24 hrs by ELISA
[PMID: 20121165]
In Vitro

Eriodictyol-7-O-glucoside (7.5-60 μM, 16 h) induces ARE-dependent luciferase activity in a dose-dependent manner in MDA-MB-231-ARE-Luc cells[1].
Eriodictyol-7-O-glucoside (0-80 μM, 0-24 h) increases Nrf2 protein level in a time-dependent and dose-dependent manner, while Keap1 level remains relatively unaffected in MDA-MB-231 cells and primary cultured astrocytes[1][[2].
Eriodictyol-7-O-glucoside (0-160 μM, 24 h) does not affect Nrf2 mRNA level but induces mRNA of HO-1, NQO1 and GCLC dose-dependently in MDA-MB-231 cells[1].
Eriodictyol-7-O-glucoside (0-80 μM, 24 h) increases Nrf2 protein level and the protein levels of HO-1, NQO1, and cGCS in a dose-dependent manner in HRMC cells[1].
Eriodictyol-7-O-glucoside (80 μM, 0-4 h) increases Nrf2 protein levels in nucleus with time and decreases Nrf2 levels in cytoplasm gradually in HRMC cells[1].
Eriodictyol-7-O-glucoside (0-80 μM, 24 h) shows a dose-dependent increase in intracellular glutathione levels in HRMC cells and primary cultured astrocytes[1][2].
Eriodictyol-7-O-glucoside (80 μM) cotreatment with Cisplatin (HY-17394) significantly improves cell survival in HRMC cells[1].
Eriodictyol-7-O-glucoside (20-80 μM, pretreatment for 2 h) reduces oxygen and glucose deprivation (OGD)-induced cell death, intracellular ROS levels, and cleaved caspase-3 expression in primary cultured astrocytes[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Eriodictyol-7-O-glucoside Related Antibodies

Western Blot Analysis[1]

Cell Line: MDA-MB-231 cells
Concentration: 0, 20, 40, 80 μM
Incubation Time: 0, 4, 6, 8, 24 h
Result: Increased Nrf2 protein level in a time-dependent and dose-dependent manner.

Real Time qPCR[1]

Cell Line: MDA-MB-231 cells
Concentration: 0, 20, 40, 80 μM
Incubation Time: 24 h
Result: Did not affect Nrf2 mRNA level.
Induced mRNA of HO-1, NQO1 and GCLC dose-dependently in MDA-MB-231 cells.

Western Blot Analysis[1]

Cell Line: HRMC cells
Concentration: 0, 20, 40, 80 μM
Incubation Time: 0, 1, 2, 4, 24 h
Result: Increased Nrf2 protein level and the protein levels of HO-1, NQO1, and cGCS in a dose-dependent manner at 24 h.
Increased Nrf2 protein levels in nucleus with time and decreased Nrf2 levels in cytoplasm gradually.
In Vivo

Eriodictyol-7-O-glucoside (30 mg/kg, i.p., once daily, 5 days) demonstrates neuroprotective efficacy in a rat model of focal cerebral ischemia (MCAO)[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Transient focal cerebral ischemia model in adult male SD rats was produced by intraluminal occlusion of the left middle cerebral artery (MCAO)[1]
Dosage: 30 mg/kg
Administration: i.p. once daily for 5 days
Result: Upregulated the expression of Nrf2, HO-1, and γ-GCS in the cortex at 8 and 24 h after reperfusion.
Reduced infarct volume and improved neurological deficit scores at 24 h after reperfusion.
Decreased the number of TUNEL-positive cells in the ischemic cortex at 8 and 24 h after reperfusion.
Alleviated morphological damage of neurons in the cerebral cortex as shown by HE staining.
Molecular Weight

450.39

Formula

C21H22O11
CAS No.
Appearance

Solid

Color

Off-white to light yellow

SMILES

O=C1C2=C(O)C=C(O[C@@H]3O[C@@H]([C@H]([C@@H]([C@H]3O)O)O)CO)C=C2O[C@H](C4=CC(O)=C(C=C4)O)C1
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (222.03 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.2203 mL 11.1015 mL 22.2030 mL
5 mM 0.4441 mL 2.2203 mL 4.4406 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (5.55 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (5.55 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.82%

SDS (393 KB)

COA (249 KB) HNMR (265 KB) CNMR (275 KB) RP-HPLC (275 KB) MS (157 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.2203 mL 11.1015 mL 22.2030 mL 55.5074 mL
5 mM 0.4441 mL 2.2203 mL 4.4406 mL 11.1015 mL
10 mM 0.2220 mL 1.1101 mL 2.2203 mL 5.5507 mL
15 mM 0.1480 mL 0.7401 mL 1.4802 mL 3.7005 mL
20 mM 0.1110 mL 0.5551 mL 1.1101 mL 2.7754 mL
25 mM 0.0888 mL 0.4441 mL 0.8881 mL 2.2203 mL
30 mM 0.0740 mL 0.3700 mL 0.7401 mL 1.8502 mL
40 mM 0.0555 mL 0.2775 mL 0.5551 mL 1.3877 mL
50 mM 0.0444 mL 0.2220 mL 0.4441 mL 1.1101 mL
60 mM 0.0370 mL 0.1850 mL 0.3700 mL 0.9251 mL
80 mM 0.0278 mL 0.1388 mL 0.2775 mL 0.6938 mL
100 mM 0.0222 mL 0.1110 mL 0.2220 mL 0.5551 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Eriodictyol-7-O-glucoside Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Eriodictyol-7-O-glucoside38965-51-4Eriodictyol 7-O-β-D-glucosideKeap1-Nrf2strokeoxygen and glucose deprivationNrf2/AREInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Eriodictyol-7-O-glucoside
Cat. No.:
HY-N3847
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Portuguese - PT (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.